Workup for Unexplained Anaphylaxis with Ehlers-Danlos Features
Despite negative initial testing, you should pursue serum tryptase levels both at baseline and during symptomatic episodes (1-4 hours after reactions), as MCAS can still be present even when standard allergy panels are negative, and this combination of hEDS-type features with recurrent anaphylaxis strongly suggests underlying mast cell dysfunction.
Diagnostic Algorithm
Step 1: Confirm Mast Cell Activation Syndrome (MCAS)
The most recent guidelines 1 provide clear diagnostic criteria for MCAS in patients with hEDS features:
- Obtain baseline serum tryptase when the patient is asymptomatic
- Repeat tryptase 1-4 hours after the next symptomatic episode
- Diagnostic threshold: An increase of ≥20% above baseline PLUS ≥2 ng/mL confirms mast cell activation 1
Critical pitfall: The statement "no marker for MCAS" likely refers to a single baseline tryptase or testing done at the wrong time. MCAS diagnosis requires paired measurements during both baseline and symptomatic periods 1. A normal baseline tryptase does NOT exclude MCAS—the diagnosis depends on the dynamic change during episodes.
Step 2: Evaluate for Clonal Mast Cell Disorders
If baseline tryptase is elevated (>11.4 ng/mL), consider underlying clonal disease 2:
- Bone marrow examination to evaluate for systemic mastocytosis or monoclonal mast cell activation syndrome
- Research shows 47% of patients with unexplained anaphylaxis have clonal mast cell disorders 2
- Patients with cardiovascular symptoms (syncope) and elevated baseline tryptase are particularly high-risk 2
Step 3: Assess for Associated Conditions
The hEDS-MCAS connection is well-established 1, 3. Evaluate for:
Postural Orthostatic Tachycardia Syndrome (POTS):
- Measure postural vital signs (heart rate increase ≥30 bpm within 10 minutes of standing)
- If positive, refer for autonomic function testing (tilt table, sudomotor testing)
- Consider autoantibody testing if POTS confirmed 1
Small fiber neuropathy and autonomic dysfunction commonly coexist with MCAS and contribute to symptoms 4
Step 4: Additional Diagnostic Considerations
While less specific, consider:
- Endoscopic biopsies with CD-117 immunohistochemical staining (duodenum or ileum) if GI symptoms present—though consensus on mast cell count thresholds remains controversial 1
- Hereditary alpha-tryptasemia testing, which can occur with anaphylaxis and MCAS 5
- Rule out other mimics: neuroendocrine tumors, vasovagal syncope 6
Key Clinical Insights
The hEDS-MCAS phenotype overlap is significant: Research demonstrates pathophysiological links through fibroblast-mast cell interactions in the extracellular matrix 3, and recent 2025 evidence shows distinctive ECM fragmentation patterns in hEDS/HSD plasma 7. The clinical presentation of MCAS frequently meets diagnostic criteria for anaphylaxis 5, explaining your patient's recurrent episodes.
Why standard allergy testing is negative: MCAS can be IgE-independent 8. The anaphylaxis results from aberrant mast cell degranulation triggered by non-allergic mechanisms, which is why traditional allergen panels fail to identify triggers 9, 6.
Referral Strategy
Once MCAS is supported by clinical and laboratory findings, refer to:
- Allergy specialist or mast cell disease research center for comprehensive evaluation 1
- Consider genetics evaluation for formal hEDS diagnosis using 2017 criteria
Management Considerations While Awaiting Workup
- Ensure patient has epinephrine auto-injectors (anaphylaxis criteria from 9 apply regardless of trigger identification)
- Consider trial of H1/H2 antihistamines and mast cell stabilizers (cromolyn sodium) 10
- Leukotriene receptor antagonists (montelukast) may provide benefit 10
The bottom line: Your patient likely has MCAS associated with hEDS/HSD, but the diagnosis was missed due to incomplete or improperly timed testing. The workup must include paired tryptase measurements during symptomatic episodes, not just baseline values.